| NCT01670565 | Hospital for Special Surgery, New York|Human Genome Sciences Inc. | Systemic Sclerosis | 2012-08 | PHASE2 |
| NCT01762852 | GlaxoSmithKline | Glomerulonephritis, Membranous | 2013-04 | PHASE2 |
| NCT04956484 | Peking Union Medical College Hospital | Lupus Erythematosus, Systemic | 2021-09-01 | PHASE4 |
| NCT07539857 | Leiden University Medical Center|GlaxoSmithKline | Kidney Transplant Rejection | 2026-04-01 | PHASE2 |
| NCT05659407 | University of Cagliari|Azienda Ospedaliero Universitaria di Cagliari | Systemic Lupus Erythematosus|Rheumatoid Arthritis|BLyS Polymorphism | 2020-07-24 | |
| NCT04097561 | National Institute of Allergy and Infectious Diseases (NIAID) | Idiopathic CD4 Lymphopenia | 2020-01-13 | PHASE1 |
| NCT01632241 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Systemic Lupus Erythematosus | 2013-02-19 | PHASE4 |
| NCT01345253 | GlaxoSmithKline|Human Genome Sciences Inc. | Systemic Lupus Erythematosus | 2011-05-23 | PHASE3 |
| NCT00071812 | Human Genome Sciences Inc. | Arthritis, Rheumatoid | 2003-12 | PHASE2 |
| NCT03844061 | Hospital for Special Surgery, New York|GlaxoSmithKline | Systemic Sclerosis | 2019-07-29 | PHASE2 |
| NCT02500251 | E. Steve Woodle|GlaxoSmithKline | Renal Transplant Rejection | 2015-06 | PHASE1|PHASE2 |
| NCT04447053 | National University Hospital, Singapore|GlaxoSmithKline | Systemic Lupus Erythematosus | 2021-11-08 | PHASE4 |
| NCT00410384 | Human Genome Sciences Inc.|GlaxoSmithKline | Systemic Lupus Erythematosus | 2006-12 | PHASE3 |
| NCT00583362 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Systemic Lupus Erythematosus | 2005-05-04 | PHASE2 |
| NCT03591380 | University of Wisconsin, Madison|GlaxoSmithKline|American College of Surgeons | Kidney Transplantation | 2019-05-14 | PHASE2 |
| NCT00424476 | Human Genome Sciences Inc.|GlaxoSmithKline | Systemic Lupus Erythematosus | 2007-05 | PHASE3 |
| NCT06576271 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2024-09-02 | PHASE1 |
| NCT01639339 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Lupus Nephritis | 2012-07-12 | PHASE3 |
| NCT01532310 | GlaxoSmithKline|PPD Development, LP | Systemic Lupus Erythematosus | 2012-07-16 | |
| NCT00732940 | Human Genome Sciences Inc.|GlaxoSmithKline | Systemic Lupus Erythematosus | 2008-10 | PHASE2 |
| NCT06411249 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2024-06-06 | PHASE4 |
| NCT01858792 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Lupus Erythematosus, Discoid | 2011-05 | |
| NCT01610492 | GlaxoSmithKline | Glomerulonephritis, Membranous | 2012-07-01 | PHASE2 |
| NCT05588830 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis|Belimumab|Telitacicept | 2022-10-20 | |
| NCT05585671 | RenJi Hospital | Whether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis | 2023-06-01 | |
| NCT04570306 | Biomedical Research Foundation, Academy of Athens|Attikon Hospital|University Hospital of Heraklion|GlaxoSmithKline | Systemic Lupus Erythematosus | 2020-12-16 | |
| NCT03154385 | Assistance Publique - H?pitaux de Paris | Immune Thrombocytopenia | 2017-03-13 | NA |
| NCT02631538 | GlaxoSmithKline | Sjogren´s Syndrome | 2016-02-17 | PHASE2 |
| NCT01583530 | Human Genome Sciences Inc.|GlaxoSmithKline | Healthy | 2011-02 | PHASE1 |
| NCT05878717 | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease|Scleroderma, Systemic | 2023-09-13 | PHASE2|PHASE3 |
| NCT01440361 | GlaxoSmithKline | Purpura, Thrombocytopaenic, Idiopathic | 2013-03 | PHASE2 |
| NCT05262686 | Peking University People´s Hospital | Systemic Lupus Erythematosus | 2022-04-01 | PHASE3 |
| NCT01894360 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2013-10-14 | PHASE1 |
| NCT04136145 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2019-10-28 | PHASE1 |
| NCT04515719 | RenJi Hospital | Systemic Lupus Erythematosus | 2021-03-10 | PHASE4 |
| NCT01484496 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Systemic Lupus Erythematosus | 2011-11-16 | PHASE3 |
| NCT00931086 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Rheumatoid Arthritis | 2009-04 | |
| NCT00583557 | Human Genome Sciences Inc. | Rheumatoid Arthritis | 2005-01 | PHASE2 |
| NCT01663623 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Vasculitis | 2013-03-20 | PHASE3 |
| NCT02270970 | Oklahoma Medical Research Foundation|GlaxoSmithKline | Systemic Lupus Erythematosus | 2014-10 | PHASE4 |
| NCT01649765 | GlaxoSmithKline|Human Genome Sciences Inc., a GSK Company | Systemic Lupus Erythematosus | 2012-09-07 | PHASE2 |
| NCT03967925 | Rachel Jones|GlaxoSmithKline|Medical Research Council|Imperial College London|University College, London|Newcastle University|University of Glasgow|University of Cambridge | ANCA Associated Vasculitis|Granulomatosis With Polyangiitis | 2019-02-01 | PHASE2 |
| NCT02124798 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2014-05-20 | PHASE2 |
| NCT04179032 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2019-11-28 | PHASE2 |
| NCT05604742 | xuna | cGVHD | 2022-01-01 | PHASE1|PHASE2 |
| NCT06381453 | University Health Network, Toronto|GlaxoSmithKline | Autoimmune Hepatitis | 2024-12-11 | PHASE2 |
| NCT07138898 | NYU Langone Health | Rheumatic Disease | 2025-09 | PHASE2 |
| NCT01705977 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2012-11-27 | PHASE4 |
| NCT00657007 | Human Genome Sciences Inc. | Systemic Lupus Erythematosus | 2002-02 | PHASE1 |
| NCT02119156 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2014-05-13 | PHASE3 |
| NCT03244059 | University of Alabama at Birmingham|GlaxoSmithKline | Chronic Obstructive Pulmonary Disease|Emphysema | 2018-08-09 | PHASE2 |
| NCT02880852 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2017-01-23 | PHASE1 |
| NCT01597492 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Systemic Lupus Erythematosus | 2012-05-31 | PHASE4 |
| NCT04629144 | Assistance Publique - H?pitaux de Paris | Vasculitis|Cryoglobulinemia | 2021-10-20 | PHASE2 |
| NCT02347891 | Northwell Health|GlaxoSmithKline | Myositis | 2015-01 | PHASE2|PHASE3 |
| NCT07340463 | Nanjing University School of Medicine | Systemic Lupus Erythematosus (SLE)|Lupus Nephritis (LN) | 2025-12-08 | PHASE2 |
| NCT01536379 | GlaxoSmithKline | Transplantation, Organ | 2013-09 | PHASE2 |
| NCT03543839 | Northwell Health|GlaxoSmithKline | Lupus Erythematosus, Systemic|Lupus Erythematosus | 2020-09-15 | PHASE4 |
| NCT04767698 | Johns Hopkins University|GlaxoSmithKline | Multiple Sclerosis | 2021-10-01 | PHASE2 |
| NCT06716606 | GlaxoSmithKline|ICON plc | Connective Tissue Diseases | 2024-12-12 | PHASE3 |
| NCT05069051 | University Hospital Tuebingen|GlaxoSmithKline | Chronic Lymphoid Leukemia in Relapse | 2022-01-19 | PHASE2 |
| NCT01142011 | Cancer Trials Australia|Human Genome Sciences Inc. | Symptomatic Waldenstroms Macroglobulinaemia | 2009-11 | PHASE2 |
| NCT04908865 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2021-10-21 | PHASE4 |
| NCT01160666 | Assistance Publique - H?pitaux de Paris|Human Genome Sciences Inc. | Sj?gren´s Syndrome | 2010-03 | PHASE2 |
| NCT00712933 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline | Systemic Lupus Erythematosus | 2008-05-30 | PHASE3 |
| NCT03747159 | Leiden University Medical Center|Dutch Kidney Foundation|GlaxoSmithKline | Lupus Erythematosus, Systemic | 2018-10-01 | PHASE3 |
| NCT01914770 | GlaxoSmithKline|Human Genome Sciences Inc. | Systemic Lupus Erythematosus | 2009-07 | |
| NCT02284984 | Leiden University Medical Center|Dutch Kidney Foundation|ZonMw: The Netherlands Organisation for Health Research and Development | Lupus Erythematosus, Systemic | 2014-03 | PHASE2 |
| NCT06572384 | GlaxoSmithKline | Lung Diseases, Interstitial | 2024-09-11 | PHASE3 |
| NCT01597622 | GlaxoSmithKline|Human Genome Sciences Inc. | Systemic Lupus Erythematosus | 2012-06-11 | PHASE3 |
| NCT03207958 | Washington University School of Medicine|GlaxoSmithKline|American Cancer Society, Inc. | Graft Vs Host Disease|Graft-versus-host-disease | 2018-05-16 | PHASE1 |
| NCT05154734 | Tianjin Medical University General Hospital|Tang-Du Hospital | NMO Spectrum Disorder | 2021-12-12 | PHASE1|PHASE2 |
| NCT04893161 | First Affiliated Hospital Xi´an Jiaotong University | Systemic Lupus Erythematosus | 2024-06-01 | PHASE4 |
| NCT01025193 | University of Pennsylvania|Human Genome Sciences Inc. | Desensitization | 2010-02 | PHASE2 |
| NCT04660565 | Peking Union Medical College Hospital | IgG4-related Disease | 2021-01 | PHASE4 |
| NCT06410833 | Peking Union Medical College Hospital|Children´s Hospital of Chongqing Medical University|Central South University|Shenzhen Children´s Hospital|The First Hospital of Jilin University|Children´s Hospital of The Capital Institute of Pediatrics|The Affiliated Hospital of Qingdao University|Children´s Hospital of Nanjing Medical University|Children´s Hospital of Fudan University|Shengjing Hospital|Shanghai Children´s Hospital|Tianjin Children´s Hospital | Sjogren´s Syndrome|Pediatric ALL | 2024-03-09 | PHASE4 |
| NCT01480596 | GlaxoSmithKline | Myasthaenia Gravis | 2013-04 | PHASE2 |
| NCT00071487 | Human Genome Sciences Inc. | Lupus Erythematosus, Systemic | 2003-10 | PHASE2 |
| NCT05917288 | GlaxoSmithKline | Systemic Lupus Erythematosus | 2023-07-07 | PHASE1 |
| NCT05020782 | University of Turin, Italy | Antiphospholipid Syndrome | 2022-06-01 | PHASE2|PHASE3 |
| NCT02260934 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) | Lupus Nephritis | 2015-07-09 | PHASE2 |
| NCT05338190 | Assistance Publique - H?pitaux de Paris|GlaxoSmithKline | Primary Immune Thrombocytopenia (ITP) | 2022-11-14 | PHASE3 |
| NCT06327724 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|GlaxoSmithKline | Systemic Lupus Erythematosus | 2023-09-01 | |
| NCT03949855 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|GlaxoSmithKline|PPD Development, LP|Rho Federal Systems Division, Inc. | Membranous Nephropathy|Nephrotic Syndrome | 2020-03-06 | PHASE2 |
| NCT05863936 | Nanjing University School of Medicine | Lupus Nephritis|Remission|Safety Issues | 2023-04-01 | PHASE3 |